A 42-year-old white male with HIV infection and Kaposi's sarcoma presented with a 4 day h/o fever, rash, arthralgias, red eyes, and headache. Physical examination revealed T102.6F, bilateral conjunctival injection with limbal sparing and no exudate, an erythematous oropharynx and fissured lips, and an erythematous, maculopapular rash on the trunk and extremities with a violaceous desquamating rash of the scrotum. Multiple, tender 1 cm anterior cervical lymphnodes were palpated bilaterally. Cardiac and abdominal exam were unremarkable.The hands and feet were edematous with red palms and soles. There was warmth, swelling, and tenderness of both ankles. Extensive evaluation including head CT scan, LP, serologic tests for Cryptococcus, Coccidioidomycosis and Treponema pallidum, cultures for virus, bacteria, and PCR for parvovirus were negative. The patient was treated initially with intravenous immunoglobulin (IVIG) and high-dose aspirin (ASA) and defervesced with resolution of his rash and peripheral edema. His conjunctival injection improved only minimally. His CD4 count was 10 cells/mL and his HIV load was Ͼ750,000 copies/uL . He was started on antiretroviral therapy. Within the next week, he relapsed with fevers, peripheral edema and worsening of conjunctival injection. Again, he was treated with IVIG and high dose ASA with resolution of the edema and fever. An initial echocardiogram revealed dilated (5-6 mm)arteries. Transesophageal echo after the second IVIG dose revealed 5 mm coronary arteries. After a third relapse, the patient was treated with plasmapharesis followed by IVIG with complete resolution of his symptoms. We reviewed 13 English language case reports (11 adults) of HIV-infected patients who developed a Kawasaki-like syndrome. Most patients experienced typical signs and symptoms of KD and the illness resolved spontaneously with no CAA, even without specific therapy. These reports raise interesting questions about the possible infectious nature of KD and the occurrence of a pediatric illness in immunosuppressed adults.
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The diagnosis of Kawasaki disease (KD) is based on 5 characteristic clinical symptoms with fever persisting at least 5 days. Recently, early diagnosis and early intravenous immune globulin (IVIG) treatment are often reported. The aim of this study is to evaluate the effectiveness and safety of early IVIG treatment. One hundred thirty nine patients (pts.) were studied. The Harada's score was used to evaluate the severity of KD. In severe cases (Harada's score Ͼ3), pts. were administered high dose IVIG(2g/kg). In other cases (Harada's score Ͻ4), pts. were administered low dose IVIG (1g/kg). Group A, which was consisted of 77 pts. were received early IVIG treatment within 4 days. Group B, which was consisted of 62 pts. ,were received conventional IVIG treatment since 5 days. All patients were treated by 10days of illness. Twenty pts. in Group A(26%) and 13 patients in Group B(21%) were not clinical responders to the initial IVIG treatment (PϭNS). No significant differences were found in incidence of coronary artery lesions between Group A (5/77, 6.5%) and Group B (5/62, 8.1%). The total duration of fever in early treatment group (Group A: 5.7Ϯ2.3days) was significantly shorter than that of conventional treatment group (Group B: 7.8Ϯ3.6days)(pϽ0.05). Conclusions: Early IVIG treatment was effective to improve KD symptoms earlier and didn't increase the complications of coronary artery lesions. The results in this study may demonstrate the merit of the further investigation of the KD as a source of baseline information for the design of future IVIG therapeutic protocols for KD. [1987] [1988] [1989] [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] were included in this case-control study. All patients had fever plus Ͼ 4 out of the 5 clinical criteria for KD. Eighty-nine patients who received treatment at day 5 or earlier were matched to 89 patients treated at days 6-9 of fever according to the closest date of KD diagnosis to the index case. Compiled data from a detailed chart review included demographics, clinical features, fever duration, investigations, disease course and response to therapy. Differences between matched case and control pairs were analyzed using t-tests and McNemar tests. RESULTS: No demographical differences were noted between the 2 groups. Patients treated on 5 days of fever had a shorter total fever duration (5.2Ϯ1.9 days vs 8.0Ϯ1.8 days, pϽ0.0001), longer fever post IVIG treatment (1.5Ϯ1.9 days vs 0.8Ϯ1.3 days, pϭ0.008) and less coronary artery ectasia at 1 year post KD onset (4% vs 16%, pϭ0.02). There was no significant difference between cases and controls in the number of patients with KD recrudescence, need for repeat courses of IVIG, need for corticosteroids, length of hospitalization or development of coronary artery aneurysms within the first 3 months. Patients who were treated at day 5 of fever, had higher levels of serum albumin (36Ϯ5 g/L vs 33Ϯ5 g/L, pϽ0.01) and serum ALT (115Ϯ155 U/L vs 46Ϯ49 U/L, pϽ0.001), as well as a lower platelet count (354Ϯ131 vs 403Ϯ166, pϭ0.02) than controls during the acute phase. CONCLU-SIONS: Early treatment of KD resulted in less coronary ectasia at one-year post KD onset but was not associated with a quicker resolution of fever, an increased number of treatment failures, an increased need for ADJ, length of hospitalization nor development of CAL. In children with fever and classical clinical and laboratory findings of KD, treatment with IVIG prior to 6 days of fever resulted in better coronary outcomes and decreased the length of time of clinical symptoms.
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